Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols
- Conditions
- Hyperlipidemia
- Interventions
- Dietary Supplement: Plant sterolDietary Supplement: Placebo
- Registration Number
- NCT01131832
- Lead Sponsor
- University of Manitoba
- Brief Summary
The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 71
- fasting serum LDL cholesterol >3.0 mmol/L
- high or low lathosterol to cholesterol ratio
- smoking
- use of lipid lowering therapy
- documented cardiovascular/atherosclerotic disease
- inflammatory disease
- diabetes
- uncontrolled hypertension
- kidney disease
- liver disease
- other systemic diseases
- cancer
- chronic alcohol consumption (> 2 servings/day)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Plant sterol Plant sterol Plant sterol supplementation, 2 grams per day of plant sterols in a margarine Plant sterol Placebo Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
- Primary Outcome Measures
Name Time Method Serum Lipids Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period Total Cholesterol, LDL-C, HDL-C, Triglycerides
Serum non-cholesterol sterols Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period Lathosterol,Lanosterol,Desmosterol,Sitosterol,Campesterol,Cholestanol,
Genotype via single nucleotide polymorphism analysis Baseline SNP genotyping in genes related to cholesterol metabolism
- Secondary Outcome Measures
Name Time Method Cholesterol synthesis measurement by deuterium incorporation Endpoint (Day 27,28) of each experimental period Cholesterol biosynthesis will be determined as the rate of incorporation of deuterium from body water into red blood cell membrane free cholesterol over a 24 hour period (day 27 to day 28 of each period). The change in deuterium enrichment within red blood cell free cholesterol will be determined as an index of synthesis, the fractional synthesis rate (FSR) of cholesterol.
Change in cholesterol absorption due to plant sterol consumption Change in cholesterol absorption from control period (measured over days 24-28) to plant sterol period (days 24-28) Ninety-six hours before the end of each period, participants will ingest 65 mg \[3, 4-13C\]-cholesterol. The 13C-cholesterol will be dissolved in 5 g of warmed margarine, and consumed on a slice of bread. A fasted blood sample will be taken at baseline on day 24 prior to isotope administration, as well as fasting samples on days 25, 26, 27 and 28 to monitor enrichment levels of 13C-cholesterol in plasma total cholesterol. The area under the curve of 13C-cholesterol from 0-96 hours (days 24-28) at the end of the control period will be compared to the same area under the curve at the end of the plant sterol period to determine the change in cholesterol absorption due to plant sterol consumption.
Trial Locations
- Locations (2)
USDA-ARS, Beltsville Human Nutrition Research Center
🇺🇸Beltsville, Maryland, United States
Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba
🇨🇦Winnipeg, Manitoba, Canada